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a b s t r a c t
Abdominal pain is the foremost complication of chronic pancreatitis (CP). Pain can be related to recurrent
or chronic inﬂammation, local complications or neurogenic mechanisms with corresponding changes in
the nervous systems. Both pain intensity and the frequency of pain attacks have been shown to reduce
quality of life in patients with CP. Assessment of pain follows the guidelines for other types of chronic
pain, where the multidimensional nature of symptom presentation is taken into consideration. Quan-
titative sensory testing may be used to characterize pain, but is currently used in a research setting in
advanced laboratories.
For pain relief, current guidelines recommend a simple stepwise escalation of analgesic drugs with
increasing potency until pain relief is obtained. Abstinence from alcohol and smoking should be strongly
advised. Pancreatic enzyme therapy and antioxidants may be helpful as initial treatment. Endoscopic
treatment can be used in patients with evidence of ductal obstruction and may be combined with
extracorporeal shock wave lithothripsy. The best candidates are those with distal obstruction of the main
pancreatic duct and in early stage of disease. Behavioral interventions should be part of the multidis-
ciplinary approach to chronic pain management particularly when psychological impact is experienced.
Surgery should be considered early and after a maximum of ﬁve endoscopic interventions. The type of
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surgery depends on morphological changes of the pancreas. Long-term effects are variable, but high
success rates have been reported in open studies and when compared with endoscopic treatment.
Finally, neurolytical interventions and neuromodulation can be considered in difﬁcult patients.
© 2017 IAP and EPC. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
In 2016, John P Neoptolemos, David C Whitcomb and Tooru
Shimosegawa embarked on a joint venture to produce the ﬁrst truly
International Guidelines on chronic pancreatitis (CP) with
endorsement from the four International Societies and support
from their respective Presidents and members in general. Although
different guidelines exist such as the recent European consensus
[1], the aim was to create a fresh clinical approach to the most
important complications of CP; not only to assist a more pragmatic
basis for patient diagnosis and management, but also to help
accelerate the assessment and hence the development of newer
therapies. The guidelines follow a new mechanistic deﬁnition of
chronic pancreatitis and conceptual model of disease initiation and
progression [2], which has been adopted by major international
societies. Producing guidelines on CP is unquestionably a consid-
erable task. Therefore the core committee for the working group
decided to divide the work into more manageable sections. Each
section focused on the key topics of CP, which were felt would
beneﬁt from consensus statements. The core committee identiﬁed
International experts to ensure multidisciplinary representation
frommost regions of the world, and theywere invited to contribute
work to their respective areas. Calls for volunteers to participate in
the process were also circulated around the four International
Societies.
Prior to the process starting, the core committees were asked to
vote on their preferred system for rating the quality evidence,
which would be used as the basis for the International CP guideline
recommendations. The consensuswas in favor of adopting a GRADE
(Grading of Recommendations Assessment, Development, and
Evaluation) approach for topics lending themselves to evidence
based statements. The guideline development process evolved over
several milestone meetings at subsequent society conferences
hosted throughout 2016.
The members of the Pain Management Working Group were
appointed to represent worldwide specialists in treatment of
pancreatic pain with representatives from gastroenterology,
endoscopy, surgery and psychiatry/psychology. This was done to
ensure an appropriate balance between the different regions and
specialties in order to achieve the most comprehensive evaluation
and recommendations. AMD was appointed as chairman of the
group. First the following questions (Q) thought to be the most
urgent and clinical relevant were made and authors assigned to
answer them. These were (author initials in brackets):
Q1. What is the natural history and burden of pain in CP (in
relation to treatment)? (DY, CMC)
Q2. Are there different types of pain in CP? (PJP, SSO, ES)
Q3. Which methods are available to assess pancreatic pain and
its response to treatment? (CMC, PJP)
Q4.What is the role of smoking and alcohol on pain treatment in
CP? (ES, PKG)
Q5. Do enzymes and antioxidants inﬂuence pain in CP? (PKG,
ES)
Q6. How can analgesics be used to treat pain in CP? (SSO, AMD,
ES)
Q7. Is endoscopic therapy effective for pain treatment in CP?
(MD, SI, SAWB)
Q8. Is ESWL effective for pain treatment in CP? (CH, MD)
Q9. Are other treatments (psychological, neurolytical etc.) of
value for pain treatment in CP? (HvG, ES, TP)
Q10. What is the optimal surgical approach to release pain in
CP? (GOC, HvG, SAWB)
Q11. When is the optimal time for surgery in painful CP? (GOC,
IED)
Q12. How to manage pain "relapse" after surgery or endoscopy?
(IED, SI)
Q13. What are the indications for referral to a specialist center
for further investigation of pain (CH, DY)
The working group then provided a structured format for sys-
tematic reviews for the different questions, and included in-
structions on how to evaluate the level of evidence and clinical
implications according to the GRADE guidelines, as adapted for
“UpToDate” (http://www.uptodate.com/home/grading-tutorial). In
the absence or limited availability of literature, the Pain Manage-
ment Working Group decided if a recommendation would be
included in the consensus report. The quality of evidence sup-
porting the different statements was graded as (i) “high” if there
was very low probability of further research completely changing
the presented conclusions, (ii) “moderate” if further research may
completely change the conclusions, (iii) “low” if further research is
likely to change the presented conclusions completely. The term
“very low” (iv) could be used if new research will most probably
change the presented conclusions completely; however, the term
was not used in the present work.
The strength of the recommendation was classed as “weak/
conditional”, “strong” or “not applicable”. This took into account
the quality of evidence, the translation of evidence into clinical
practice, and any relevant uncertainties relating to population risk.
Finally, to gauge the level of objective support from the
participating international expert panel, the members of the Pain
Management Working Group voted using a nine-point Likert scale
on their level of agreement with the recommendations and their
GRADE score. Voting results were classiﬁed under “agreement” as
either; strong (80% of votes were 7 or above), conditional (65%
of votes were 7 or above), and weak (<65% of votes were 7 or
above).
All authors reviewed the ﬁnal manuscript to ensure the general
relevance and applicability of the conclusions. The European
Pancreatic Club conference in July 2016 hosted the ﬁrst milestone
meeting for the process of developing the International CP guide-
lines. AMD presented the outcomes of “the Pain Management
Working Group” to the meeting and the work is summarized in this
manuscript.
In the present document, the recommendations are listedwith a
summary of the most relevant information and references. How-
ever, due toword limitsmost information could not be included and
the reader is encouraged to see the Appendix where the full text
and references are found.
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Q1. What is the natural history and burden of pain in chronic
pancreatitis?
Abdominal pain is the most frequent symptom of CP. However, the
severity, temporal nature, and natural history of pain is highly
variable (Quality assessment: moderate; Recommendation: strong;
Agreement: strong)
While variation in disease estimates exist, the prevalence of CP
has been approximated at ~50/100,000 population [3]. Abdominal
pain, alone or during episode(s) of acute exacerbation of pancrea-
titis, is the most common symptom. Patients typically describe
their pain as a dull, sharp or nagging sensation in the upper
abdomen, which can radiate to the back, and often presents after or
worsened by food intake. In natural history studies, pain was
observed as the initial presentation in ~75% of patients [4], and
present during the clinical course in 85e97% [4e7]. Patients with
early onset-disease and those with alcohol etiology are more likely
to have pain [4,5]. According to the burn-out hypothesis, a majority
of patients with chronic pancreatitis achieve lasting pain-free sta-
tus during the clinical course [5,8]. This claim, however, has not
been substantiated by others, mainly due to persistence of pain
symptoms in a signiﬁcant fraction of patients with ongoing pain
even after 10 or more years of disease [9]. Naturally, CP is a major
burden for patients and both pain intensity and the frequency of
pain attacks have been shown to reduce quality of life substantially
[10,11].
Q2. Are there different types of pain in CP and what does it
mean for treatment?
Pain in CP remains poorly understood and inadequately correlated
with neurobiological mechanisms. By deﬁnition, CP is characterized
by inﬂammation but unlike other inﬂammatory disorders, there is a
paucity of therapeutic attempts targeting this particular aspect of
pathophysiology. On the other hand, there are striking changes in
structure and function in both the peripheral and central nervous
system in this condition, lending plausibility to a maladaptive state
that includes both neuropathic and dysfunctional pain. In the
absence of effective anti-inﬂammatory approaches, it is clearly
important to focus on the alteration of function that accompanies
these changes in the nociceptive system as a potential therapeutic
target. (Quality assessment: low; Recommendation: strong;
Agreement: strong)
An early approach to classifying pain in CP was made by Amman
et al. [8] “A-type pain” pattern was seen in patients with one or
more discrete episodes of pain interspersed with pain-free in-
tervals. Slightly less than half (44%) of patients also had “B-type
pain” described as persistent (i.e. daily) pain over prolonged pe-
riods of time and/or closely clustered exacerbations of severe pain.
A later study demonstrated that clinical outcomes were best pre-
dicted when “intermittent” (about 45% of patients) versus “con-
stant” pain were compared, thus echoing the earlier binary
classiﬁcation [10].
Putative neurobiological causes of pain
Inﬂammation: It is intuitively appealing to suggest that a sig-
niﬁcant, if not major, type of pain in CP is inﬂammatory in nature.
Animal models have also shown that inﬂammatory pain in CP is
mechanistically generally similar to other chronic inﬂammatory
conditions. The expression of numerous algogenic factors is altered
in experimental models as well as in human pancreatic specimens.
Some but not all of these factors andmolecules have been shown to
correlate with pain severity, although causation is not proven
[12e14]. On the other hand, “intermittent” episodes of pain
observed in patients correspond not always to a “ﬂare” of inﬂam-
mation. Correspondingly, in a large prospective cohort study, there
was no correlation between temporal pattern and the presence or
absence of radiological evidence of inﬂammation or obstructive
pathology [10,15].
Neuropathy: Animal models have provided convincing evidence
that CP results in hypersensitivity of pain responses to pancreatic
stimulation, associated with impressive sensitization of the pri-
mary nociceptive neurons with speciﬁc electrophysiological and
molecular changes. Themodels also suggest a component of central
sensitization including potential roles for spinal glial activation and
descending inhibitory pathways [16e18]. Correspondingly, patients
with severe CP have lower pain thresholds and expanded pain
referral areas than patients with moderate CP or healthy volun-
teers, which many be a reﬂection of spinal sensitization [19,20].
Alterations in descending inhibitory inﬂuences on spinal nocicep-
tive neurons have also been shown in humans [19e22]. Finally,
electroencephalographic and imaging ﬁndings in patients with CP
similarly show functional changes suggesting a maladaptive pain
response [20,23e26].
Q3. Which methods are available to assess pancreatic pain and
its response to treatment?
Assessment of pain in CP follows the guidelines for other types of
chronic pain, where the multidimensional nature of symptom
presentation is taken into consideration. Only a few instruments
have been validated for subjective pain assessment in CP; however,
several appropriate measures exist despite not being rigorously
validated in this population. (Quality assessment: moderate;
Recommendation: strong; Agreement: strong)
Subjective verbal reports
One-dimensional scales (usually pain intensity)
One-dimension scales assess a single element of pain, and allow
for a simple and fast method for patients to self-report the sub-
jectively experienced intensity of their pain, but can oversimplify
the pain experience [27].These scales use numeric (often 0e10),
verbal or visual descriptors to quantify pain or the degree of pain
relief. Numerical scales, such as the visual analogue scale (VAS), are
commonly applied to assess the intensity of pain in CP patients, but
should be combined with a standardized registration of the pain
pattern in time [10].
Multidimensional scales
Multidimensional scales measure several of the above over-
viewed aspects of pain, including its intensity, nature and location,
and in some cases, pain's impact on mood or activity level. A
commonly used measure in CP, the Izbicki pain score was devel-
oped to capture some of the aforementioned dimensions of pain
and provide a surrogate score [28]. It has, however, never been
strictly validated in patients with CP. The Brief Pain Inventory (BPI)
is commonly used with chronic pain patients and validated in CP. It
quantiﬁes intensity as well as pain's interference in mood, ability to
work etc., and correlates with quality of life in CP patients [11]. The
McGill Pain Questionnaire is another commonly used survey that
assesses three aspects of the pain experience, including sensory,
affective, and evaluative dimensions and likely a more appropriate
pain assessment measure in CP patients than unidimensional
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Quantitative sensory testing (QST)
Pain sensitivity can be reliably assessed and quantiﬁed in the
laboratory using quantitative sensory testing (QST) [30]. These
calibrated and standardized methods for delivering noxious stimuli
under controlled conditions [31] are reﬂective of clinical conditions,
as subjects who rate QST stimuli as most painful [32,33], or show
heightened central sensitization [34,35] report the most frequent,
disabling clinical pain. Dynamic QST techniques have the potential
to more directly assess CNS pain-modulatory processes [36]. QST is
frequently employed to evaluate treatment responses among CP
patients. For example, pregabalin inhibited central sensitization
[37], and oxycodone was found to be more effective than morphine
on visceral pain in patients with CP [38].
Q4. What is the role of smoking and alcohol on pain
treatment in CP
Abstinence from alcohol and smoking, in addition to adequate
treatment, should be strongly advised in patients with CP (Quality
assessment: moderate (alcohol) to weak (smoking); Recommen-
dation: strong; Agreement: strong)
Alcohol: High alcohol intake is a risk factor for acute and chronic
pancreatitis [39], and abstinence from alcohol is associated with
reduction in frequency of recurrence of pancreatitis [40,41]. Phar-
macological treatment is often necessary to ensure that the pa-
tients refrain from alcohol intake. Benzodiazepines and mood
stabilizers such as carbamazepine are safe and efﬁcacious in
treating moderate symptoms of alcohol withdrawal [42]. Only
three medications are used for treatment of alcohol dependence;
naltrexone, acamprosate and disulﬁram. Naltrexone has strong
support in reducing relapse in alcoholics [43], while acamprosate
has shown efﬁcacy in some [44] but not all trials [45]. While
disulﬁram has been widely used, there is no clear clinical trial data
supporting positive outcomes [46].
Non-pharmacological treatments have also been widely used.
Several psychosocial interventions have shown signiﬁcant behav-
ioral change in patients with alcohol dependence including
cognitive behavioral therapy [47,48]. Self-help organizations such
as Alcoholics Anonymous can also be helpful [49].
Tobacco: Several studies have shown that smoking tobacco,
particularly cigarettes increased the risk for developing both acute
[50,51] and chronic pancreatitis [52,53] and this relative risk is
dose-dependent. More than 80% of patients with alcoholic chronic
pancreatitis are smokers and smoking potentiates alcohol toxicity
in dose-dependent way [53]. While cigarette smoking is often
present in alcohol abuse, studies showing smoking as an inde-
pendent predictive factor are emerging [50,54]. However, no study
has evaluated the effect of smoking cessation on pain in patients
with CP.
Pharmacological treatment: Logically, smoking cessation should
be a strong recommendation. In a recent Cochrane review nicotine
replacement, bupropion, varenicline, and cytisine, another partial
nicotine receptor agonist, had the greatest evidence for improving
the chances of quitting [55].
Non-pharmacological treatment: Cognitive behavioral therapy
combined with smoking cessation medications can be effective in
smokers who are motivated to quit [56]. Mindfulness-based ther-
apy may also help with recovery from smoking relapse [57].
Q5.Do enzymes and antioxidants inﬂuence pain in CP?
Pancreatic enzyme therapy with high protease content may be
tried as an initial treatment for pain relief in patients with CP.
Furthermore; combination of antioxidants in sufﬁcient dosages
should be included in the armamentarium of pain treatments
(Quality assessment: moderate; Recommendation: strong; Agree-
ment: weak)
The pathophysiological basis of using pancreatic enzymes for
pain in CP is related to the hypothesis that nutrients stimulate the
release of cholecystokinin releasing factor (CRF) from the duo-
denum [58]. The CRF then releases cholecystokinin, which stimu-
lates pancreatic secretion and this may increase intraductal
pressure in patients who have ductal obstruction. Theoretically, the
pancreatic enzymes degrade CRF thus limiting the release of
cholecystokinin and subsequently decrease pancreatic secretion.
Six randomized clinical trials have been reported on the effect of
pancreatic enzymes in pain relief. In a review of these [59], pain
relief using pancreatic enzymes as tablets was noted in two trials
[60,61] and no beneﬁt was noted in 4 trials that used acid-protected
capsule form of enzymes [62e65]. The reason could be that
pancreatic enzymes were not released in the duodenum in the
acid-protected form. If enzyme therapy is tried for pain relief, the
preparations should be uncoated, contain large amounts of pro-
teases (>25,000 USP units per tablet) and be given in a dosage of
four to eight tablets four times a day.
Antioxidants may also be helpful in pain treatment. Oxidative
stress as a mechanism of inﬂammation in CP has been shown for
the past 30 years [66e70]. Consequently, antioxidant supplemen-
tation has been used to ameliorate oxidative stress and relieve pain
in patients with CP. Recent meta-analyses of randomized controlled
trials have shown beneﬁcial effect of antioxidants in patients with
CP [71e73]. A combination of antioxidants (b-carotene, vitamin C,
vitamin E, selenium, and methionine) has shown signiﬁcant pain
relief while studies with single antioxidant therapy showed no
signiﬁcant pain relief. A recent study has shown that a combination
of pregabalin and antioxidants resulted in beneﬁt in those who had
recurrence of pain after surgical and/or endoscopic therapy [74].
Q6. Which analgesics are recommended for pain in chronic
pancreatitis?
Currently the standard guideline for analgesic therapy in CP follows
the principles of the “pain relief ladder” provided by the World
Health Organization (WHO) adjusted to the pain characteristics of
this condition (Quality assessment: moderate; Recommendation:
strong; Agreement: strong)
The standard guidelines for analgesic therapy in CP follow the
principles of the “pain relief ladder” provided by the World Health
Organization (WHO). This approach enables a simple stepwise
escalation of drugs with increasing analgesic potency (level I-III)
until pain relief is obtained, with simultaneous monitoring and
handling of side effects [75].
Simple analgesics are used as a cornerstone in pain treatment
and paracetamol is the preferred level I drug due to its limited side
effects. The non-steroidal anti-inﬂammatory drugs (NSAIDs)
should in general be avoided due to their gastrointestinal toxicity
[76]. This may especially be relevant in CP as patients are already
predisposed to peptic ulcers [77].
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Adjuvant analgesics are a heterogeneous group of drugs initially
developed for indications other than pain and include antidepres-
sants, anticonvulsants as well as anxiolytics (and spasmolytics in
the gut). Although adjuvant analgesics have been widely used in
the clinic to treat pain in CP, only pregabalin has been investigated
in this patient group andwas found to induce amoderate pain relief
[78].
Anti-depressive drugs are widely used pain treatment in func-
tional visceral pain disorders and although no data exist in CP, their
positive effects in patients with neuropathic pain (thought to be
prevalent in CP) makes them attractive [79]. It is, however, unclear
if their effect is mediated through direct analgesic effects or indi-
rectly by reducing anxiety and depression [80].
Opioid analgesics seem to be a necessary step to dampen pain in
many patients with CP, and it is mandatory that pancreatologists
understand the complexity of opioids [81]. Opioid based treat-
ments are often associated with many severe adverse effects such
as constipation or opioid induced hyperalgesia [82,83]. Patients on
long-term opioid therapy must be kept under close clinical sur-
veillance and it shall be stressed that only about 25% of patients
beneﬁt from treatment. Some drugs such as tramadol possesses
both a weak opioid agonist activity along with an effect on
noradrenaline and serotonin uptake [84]. Tramadol is often the
preferred level II analgesia and was shown to be superior to
morphine in patients with CP, with fewer gastrointestinal side ef-
fects for the same level of analgesia [85]. Transdermal adminis-
tration of opioids should be reserved to patients having trouble
with tablet ingestion. There is marked inter-individual variability in
responsiveness to different opioids, and often a trial of an alter-
native opioid is indicated [81,86].
In some patients unconventional treatment with drugs such as
ketamine is beneﬁcial, but only in the hands of pain specialists.
Somastotatin-analogue inhibits pancreatic secretion and may
theoretically alleviate pain through reduction of pancreatic ductal
pressure. However, there are conﬂicting data about the efﬁcacy.
Other drugs including clonidine, benzodiazepines, anti-psychotics
or cannabinoids may also be beneﬁcial in difﬁcult cases.
In clinical practice pain treatment is mainly guided by evidence
from somatic pain studies together with individual experience and
traditions. In Fig. 1 the pain treatment algorithm used at Centre for
Pancreatic Diseases, Aalborg University Hospital, Denmark is
shown. This includes neurophysiological and psychological testing.
For example segmental hyperalgesia of the epigastric skin area
(pancreatic viscerotome) may predict the response to gabapenti-
noids [87].
Q7. Is endoscopic therapy effective for pain treatment in CP?
The best candidates for successful treatment of painful CP with
ﬁrst-line endoscopic therapy are patients with distal obstruction of
the main pancreatic duct (single stone and/or single stricture in the
head of the pancreas) and in the early stage of the disease. Endo-
scopic therapy can be combined with Extracorporeal Shock Wave
Lithotripsy (ESWL) in the presence of large (>4 mm) obstructive
stone(s) located in the pancreatic head, and with ductal stenting in
the presence of a dominant main pancreatic duct stricture that
induces a markedly dilated duct. (Quality assessment: moderate;
Recommendation: strong; Agreement: conditional)
Endoscopic therapy (ET) in painful CP is based on the rationale
that pain is related to an outﬂow obstruction of the main pancreatic
duct (MPD) due to stricture(s) or pancreatic intraductal stone(s).
Endoscopic retrograde cholangio-pancreatography (ERCP) can
achieve MPD drainage by sphincterotomy of the major and/or
minor papilla, by short-term stent placement or by pancreatic stone
extraction, usually after fragmentation with ESWL.
The effectiveness of ET is usually the result of these combined
procedures; all of these are aimed to restore drainage of the MPD.
With this approach about 60% experience complete or partial pain
relief both in the short (<2 years) and long-term (>5 years) follow-
up. However, the quality of evidence of reported results remains
low in most of these retrospective observational non-randomized
studies (see Tables and studies in Appendix). Only two random-
ized controlled trial (RCT) compared ET and surgery, and both
favored surgery [88,89]. There were, however, several shortcom-
ings. Among them was the low technical success rate [88] and
suboptimal procedures [89] compared with previous studies
(Tables in Appendix). Contrary to surgery, ET is possible in patients
with risk factors such as older age and co-morbidities. Factors
predicting favorable clinical outcome after ET ± ESWL have been
identiﬁed and are shown in Fig. 2 [90,91] (see also Tables in
Appendix), and if clinical success can be obtained with  5 endo-
scopic interventions, the patient will probably achieve long-term
favorable outcome.
Q8. Is ESWL effective for pain treatment in CP?
In patients with uncomplicated painful calciﬁed CP, ESWL alone is a
safe and effective treatment. Best candidates for beneﬁting from
initial ﬁrst-line ESWL are patients with obstructive calciﬁcations, >
4 mm conﬁned to the head of pancreas. Combining systematic
endoscopical therapy with ESWL adds to the cost of patient care, at
the same time not probably improving the outcome of pancreatic
pain (Quality assessment: moderate, Recommendation strong;
Agreement: conditional).
ESWL for pancreatic stones is indicated for patients with all of
the following:
1. recurrent attacks of pancreatic pain
2. moderate to marked changes in the pancreatic ductal system
3. obstructing ductal stones (minimal diameter: 2e5 mm, calciﬁed
or radiolucent) [92].
Regardless of the method of shock waves generation ESWL
provides high rates of stones fragmentation (average of 91% ranging
from 54 to 100%) [92]. ESWL was proven useful for treating CP
related pain in several meta-analyses [93,94] where the pooled
proportion of patients with absence of pain at follow-up was about
50% and narcotic use was decreased in 80%. In a prospective ran-
domized study that compared ESWL alone with ESWL combined
with endoscopy [95], there was no evidence that the combination
of endoscopy and ESWL was better than ESWL alone for pain
treatment. Data regarding duct clearance have been somewhat
conﬂicting ranging between similar for the procedures alone [96] to
a better outcome for the combined procedures [97]. Factors asso-
ciated with complete stone clearance included the presence of a
single stone vs. multiple stones [98,99], the absence of a MPD
stricture [98] and a lower density of stones (<820 Hounsﬁeld units)
[100].
After treatment with ESWL (alone or combined with endoscopic
drainage), most of the patients who experienced pain relapses
developed them during the ﬁrst two years following treatment
[90,95,101]. Pain relapse occurred signiﬁcantly more frequently in
patients with incomplete removal of stones after the initial therapy
and in those with a MPD stricture [98]. Other factors associated
with long-term pain relief are short disease duration, low fre-
quency of pain attacks before treatment, complete ductal stone
clearance, absence of MPD stricture and discontinuation of alcohol
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Fig. 1. Suggested algorithm for pharmacological treatment (grey boxes) of pain in chronic pancreatitis. In most cases, combination therapies are necessary. Treatment with
antidepressives is guided by psychological evaluation including assessment of catastrophizing, depression etc. In case gabapentinoids are considered we use evaluation of the ratio
between segmental and generalised hyperalgesia (see text). Of note, treatment with gabapentinoids, TCA, SNRI (or SSRI in selected cases) should be titrated slowly until sufﬁcient
effect or intolerable adverse effects occur. Treatment shall be individualised due to major differences in receptor properties and analgesic mechanisms between patients. NSAIDs are
normally not indicated and should be used carefully. Opioids shall be avoided if possible due to the major side effects on the gastrointestinal tract etc., but in severe pain they may be
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and tobacco [90,98,101,102].
Q9. Are other treatments (neurolytical, psychological, etc.)
effective for pain management in CP?
Neurolytical interventions can be used in selected patients with
painful CP who have failed endoscopic and surgical treatment.
Thoracoscopic splanchnic denervation is more effective regarding
long-term pain relief in patients who are not on chronic opioid
treatment. Behavioral interventions should be part of the multi-
disciplinary approach in CP pain particularly when patients
experience psychological impact of pain and quality of life has
decreased. Early intervention in children may be particularly
important. (Quality assessment: low; Recommendation: strong;
Agreement: conditional)
Neurolytic interventions: Celiac plexus blocks and splanchnic
nerve ablation of patients with CP are generally advised when other
medical treatments for pain have failed. Several techniques for
percutaneous celiac plexus blockade have been described [103], but
pain relief only lasts for short term with a risk for side effects such
as postural hypotension and diarrhea. Therefore celiac plexus block
is nowadays rarely applied in CP. Thoracoscopic splanchnicectomy
was ﬁrst described as a minimally invasive therapy for pain in 1994
[104]; however, to date no RCT has been done. Preoperative opioid
use, duration of disease and pain seem to impair long term results
probably due to central sensitization [105].
There are only a few studies of spinal cord stimulation and
transcranial magnetic stimulation in chronic pancreatitis [106,107].
Pain relief by spinal cord stimulation was achieved in 66% of pa-
tients, but a drawback of the procedure is its invasiveness. Repet-
itive TMS holds promise for treating depression in chronic
pancreatitis patients with a possible concurrent pain relieving
effect.
Psychological/psychiatric interventions: There is a paucity of
studies in CP, but in other chronic pain conditions psychological
interventions have been shown to be efﬁcacious [108,109]. In-
terventions include cognitive behavioral therapy, mindfulness ap-
proaches, hypnosis etc. [110e113].
Children with CP represent an important subgroup who expe-
riences frequent pancreatitis-related abdominal pain [114], but
there are no studies conducted to date. However, psychological
treatments for other forms of pediatric chronic pain have promising
effects.
Q10. What is the optimal surgical approach to relieve pain in
CP?
Depending on the morphological changes of the pancreas and pain
processing status a (partially) resection, decompression of the
pancreatic duct or combined interventions can be performed to
reduce pain. Long-term effects are variable, but success rates up to
80% have been reported. The emerging role of total pancreatectomy
as initial surgical treatment looks promising but needs further
investigation (Quality assessment: moderate; Recommendation:
strong; Agreement: conditional)
Surgical options for pain are classiﬁed into three categories: a)
decompression (focusing on ductal hypertension), b) resection
(focusing on inﬂammatory masses and stones in the pancreatic
head) and c) combined procedures. Although long-term results of
surgery are promising, most of studies to date are observational or
only compare different invasive procedures. There are several
procedures available dependent of the indication (see Appendix). In
randomized controlled trials, tailored organ-sparing procedures
have been found to be superior to Whipple or the pylorus-
preserving Whipple procedure in regard to pain relief (75%) and
morbidity (20%) [115,116]. An indication for total pancreatectomy
(with/without islet autotransplantation) is to palliate pain espe-
cially before diabetes mellitus has developed [117,118]. When cen-
tral sensitization is present endoscopic and/or surgical therapy has
a higher risk of failure. Factors that are relevant in developing
sensitization are duration of the disease, age, pain history and
previous invasive treatment [119]. Surgery has to be tailored to the
needs of patients and should be organ sparing in a high-volume
center with expertise in pancreatic surgery.
Q11. When is the optimal time for surgery in painful CP?
Current evidence on the timing of surgery for painful CP suggests a
beneﬁcial role for early surgery, i.e. 1) within the ﬁrst 2e3 years
after diagnosis or symptom onset, 2) for patients who had equal to
or fewer than 5 endoscopic procedures, and 3) for patients who
have not yet required opioid analgesics for medical pain treatment
(Quality assessment: low; Recommendation: weak; Agreement:
strong).
Although there are no prospective controlled studies that spe-
ciﬁcally addressed the timing of surgery for painful CP, increasing
amount of evidence suggests that surgery should be considered
early for better pain outcomes. In a systematic review that analyzed
the role of timing, it was found that early surgery was associated
with a greater probability to attain postoperative pain relief [120].
The optimal cutoff point for was found 26.5 months or less [121].
Preoperative opioid use and 5 or more endoscopic interventions
also seems to have negative inﬂuence [122,123]. In patients with
obstruction of the duct system timing can be decisive for the
outcome.
Q 12. How to manage pain "relapse" after surgery or
endoscopy for painful CP?
Current evidence suggests that the ﬁrst step for the management of
pain relapse should be exclusion of obstructing stones or strictured
anastomosis via imaging, followed by a limited number endoscopic
interventions, and early consideration of re-surgery to achieve pain
prescribed for limited periods and the physician shall always be aware of opioid induced bowel dysfunction and hyperalgesia (narcotic bowel).
“Plus sign” indicate sufﬁcient/satisfactory effect.
“Minus sign” indicate insufﬁcient effect
ESWL: extracorporal
shock wave lithotrypsy
PCM: paracetamol
NSAID: non-steroidal anti-inﬂammatory drugs
TCA: tricyclic antidepressives
SNRI: serotonin-noradrenalin reuptake inhibitors
SSRI: selective serotonin reuptake inhibitors
OIBD: opioid induced bowel dysfunction.
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control (Quality assessment: weak; Recommendation: strong;
Agreement: weak).
After both surgery [124e126] and endoscopy [127], the long-
term (5-year) pain free status is around 50e60%. Patients with
pain relapse after endoscopical treatment may beneﬁt of combined
antioxidant-pregabalin therapy [74]. There is lack of sufﬁcient ev-
idence for concrete recommendations for managing pain relapse
after surgery, but surgeons should consider that any kind of sub-
sequent treatment may be subject to failure due to irreversible
neuropathic alterations [79,128]. In all cases, it is crucial to ﬁrst
exclude more simple reasons for therapy failure such as obvious
stricture of anastomosis, or obstructing stones in the pancreatic or
bile duct [129]. Furthermore, it should be considered that a salvage
operation for pain relapse may end up in a total pancreatectomy.
Q13. What are the indications for referral to a specialist center
for further investigation of pain?
All patients with presumed or established diagnosis of CP should be
routinely referred to specialist pancreatic centers for investigation
and treatment of their disease (Quality assessment: moderate;
Recommendation: strong; Agreement: strong).
Referral should be considered when non-specialist manage-
ment is failing, chronic pain is poorly controlled, there is signiﬁcant
distress, and/or where speciﬁc specialist intervention or assess-
ment is considered. A systematic review of observational studies
(although not in CP) concluded that a longer delay between
specialist referral and specialist consultation resulted in poorer
health and pain management [130].
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.pan.2017.07.006.
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